Global Juice Testing Industry on Track for Robust 8.2% CAGR Growth
Delray Beach, FL, June 25, 2025 (GLOBE NEWSWIRE) -- The juice testing market size is on an upward trajectory, expected to rise from USD 0.86 billion in 2025 to USD 1.28 billion by 2030, at a CAGR of 8.2%. This growth is fueled by rising health awareness, strict regulatory standards, and increasing demand for safe, high-quality beverages across the globe.
Why Juice Testing Is Becoming a Non-Negotiable
Consumers today are more conscious than ever about what they drink. The surge in contamination incidents, food fraud, and allergen-related recalls has made safety testing a top priority for juice manufacturers. Combined with expanding global juice production and stricter international trade rules, the need for reliable testing protocols has never been greater.
Public Health Concerns Are Reshaping the Industry
Since the 1990s, juice-related outbreaks involving E. coli, Salmonella, and Cryptosporidium have sparked serious public health alarms. These issues led to the rollout of HACCP-based safety regulations by the U.S. FDA, which set the standard for the global juice testing landscape. The continued push for safer beverages is driving rapid advancements in testing technologies and lab services.
Europe Emerges as the Powerhouse of Juice Testing
European juice testing industry is poised to lead the market over the next five years, thanks to its tough regulatory framework and high consumer expectations. Countries like Germany, France, the UK, and Italy boast world-class laboratories that support extensive chemical, microbial, and allergen testing. The region's focus on organic and clean-label juices also strengthens its leadership position in the global market.
Chemical Testing: The Backbone of Quality Assurance
Chemical testing holds a commanding share in the juice testing sector. From acidity levels and preservatives to trace contaminants, chemical analysis ensures every product meets safety and labeling standards. With advancements in chromatography and spectrometry, manufacturers are better equipped to deliver safe, compliant, and high-quality juices.
Request a call with our Analysts to tailor solutions for your business
Mixed Juices Create a Demand for Deeper Testing
Mixed juices—popular for their nutritional diversity and innovative flavors—are driving the need for more comprehensive testing. These blends often contain multiple fruits and vegetables, making testing crucial to ensure consistency, accurate labeling, and safety. As consumers seek functional beverages and clean-label options, manufacturers are ramping up quality control to stay competitive.
Latest Moves Shaping the Juice Testing Landscape
Intertek launched a new regional headquarters in Riyadh (Feb 2025), improving access to localized compliance and testing.
Mérieux NutriSciences expanded its global lab footprint by acquiring Bureau Veritas' food testing operations (Feb 2025).
SGS opened a new facility in New Jersey (Oct 2024), boosting its juice testing capabilities in North America.
ALS introduced InviRapid allergen detection strips (Aug 2024), enabling faster on-site safety checks.
Who's Leading the Market?
The juice testing industry is supported by a robust ecosystem of global players, including:
Eurofins Scientific
SGS Société Générale de Surveillance SA
ALS
Intertek Group plc
Mérieux NutriSciences
Certified Group
TÜV SÜD
Symbio Labs
Alfa Chemistry
FoodChain ID
AGQ Labs
Tentamus
The Road Ahead: Safe, Transparent, and Trusted Juices
With consumer demand for transparency and health-focused beverages rising, the role of juice testing is only becoming more critical. Whether it's through advanced technology, quicker turnaround times, or stricter compliance requirements, the industry is evolving rapidly. As safety becomes a selling point, thorough testing is set to become a core pillar of every juice brand's strategy.
Scale Your Reach in a Growing Market—Connect with Leading Juice Testing Manufacturers
CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Visit Our Website: www.marketsandmarkets.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Market Sentiment Around Loss-Making Orion Energy Systems, Inc. (NASDAQ:OESX)
With the business potentially at an important milestone, we thought we'd take a closer look at Orion Energy Systems, Inc.'s () future prospects. Orion Energy Systems, Inc., together with its subsidiaries, researches, designs, develops, manufactures, markets, sells, installs, and implements energy management systems for commercial office and retail, area lighting, industrial applications, and government in North America and Germany. The US$22m market-cap company announced a latest loss of US$12m on 31 March 2025 for its most recent financial year result. As path to profitability is the topic on Orion Energy Systems' investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts' expectations for the company. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Consensus from 2 of the American Electrical analysts is that Orion Energy Systems is on the verge of breakeven. They expect the company to post a final loss in 2027, before turning a profit of US$467k in 2028. So, the company is predicted to breakeven approximately 3 years from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 67%, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. Underlying developments driving Orion Energy Systems' growth isn't the focus of this broad overview, however, take into account that by and large a high growth rate is not out of the ordinary, particularly when a company is in a period of investment. See our latest analysis for Orion Energy Systems One thing we would like to bring into light with Orion Energy Systems is its relatively high level of debt. Typically, debt shouldn't exceed 40% of your equity, which in Orion Energy Systems' case is 87%. Note that a higher debt obligation increases the risk around investing in the loss-making company. There are too many aspects of Orion Energy Systems to cover in one brief article, but the key fundamentals for the company can all be found in one place – Orion Energy Systems' company page on Simply Wall St. We've also compiled a list of key aspects you should further examine: Historical Track Record: What has Orion Energy Systems' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Orion Energy Systems' board and the CEO's background. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here. — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Small-cap and under-the-radar stocks with strong growth possibilities merit closer investor attention. 10 stocks we like better than TransMedics Group › There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving. Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases. Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio. Certara (NASDAQ: CERT) is poised to capitalize on the transformation in medicine driven by artificial intelligence (AI), providing bio-simulation software and services that accelerate drug development. The company plays a crucial role in the pharmaceutical industry. Over 90% of all novel drugs approved by the Food and Drug Administration (FDA) since 2014 have leveraged its technology. Its AI-driven solutions enhance research and development (R&D), enabling faster and more precise drug development. Certara deserves a closer look by investors seeking to tap into the AI-driven healthcare transformation. Beam Therapeutics (NASDAQ: BEAM) is a clinical-stage biotech pioneering precision-based gene editing therapies for genetic diseases, including sickle cell disease. Its innovative technology enables precise single-nucleotide DNA changes, potentially offering a safer alternative to traditional CRISPR genetic engineering. Beam has reported early success in gene correction, with its lead candidate, BEAM-101, in phase 1/2 trials for sickle cell disease. While the company still has a lot to prove, its differentiated approach and clinical progress position it for remarkable growth in the long term. Inspire Medical Systems (NYSE: INSP) develops implantable neurostimulation devices for obstructive sleep apnea, offering its FDA-approved Inspire therapy as a noninvasive alternative to CPAP machines. In its first quarter (the period ended March 31), revenue surged 23% year over year to $201 million, driven by growing U.S. adoption and new international approvals. With increasing demand for sleep apnea treatment, Inspire has a significant opportunity to capture market share. Insulet (NASDAQ: PODD) specializes in tubeless insulin pump technology. Its Omnipod system simplifies diabetes management for Type 1 and insulin-dependent Type 2 patients globally, offering convenience and improved outcomes. With a 2025 revenue growth target of 19% to 22%, the company is poised for continued expansion, particularly in underpenetrated international markets. Insulet's strong growth trajectory positions it to reward shareholders further. Krystal Biotech (NASDAQ: KRYS) focuses on rare skin diseases. Its FDA-approved gene therapy, Vyjuvek, for dystrophic epidermolysis bullosa (fragile skin that blisters easily) is expected to approach $400 million in revenue this year, solidifying its position as a best-in-class treatment. Vyjuvek's success validates Krystal's R&D, bolstering confidence in its pipeline and unlocking added market potential. LifeMD (NASDAQ: LFMD) operates a telehealth platform providing specialized virtual care in weight loss, men's health, and dermatology. A partnership with Novo Nordisk to offer Wegovy, a leading GLP-1 treatment, has driven impressive growth, with first-quarter revenue surging 49% year over year for the period ended March 31. LifeMD could expand its growing user base into a comprehensive health management ecosystem to fuel growth and solidify its telehealth leadership. Option Care Health (NASDAQ: OPCH) is the leading U.S. provider of home and alternative-site infusion services, delivering crucial therapies for chronic and acute conditions like cancer, immune deficiencies, and infections. As the healthcare industry shifts toward more personalized and cost-effective care, Option Care Health is in position to capitalize on the strong demand, with its extensive network and high-quality services. Tempus AI (NASDAQ: TEM) harnesses artificial intelligence to advance precision medicine, using its collection of clinical and molecular data from more than 40 million patients to power diagnostics in oncology, cardiology, and beyond. The company projects its revenue to climb by more than 80% this year, to about $1.3 billion. Tempus AI's scalable platform and extensive data ecosystem present substantial opportunities for expansion and impact in personalized healthcare. TransMedics Group (NASDAQ: TMDX) has revolutionized organ transplantation with its Organ Care System (OCS), the only FDA-approved device for heart, lung, and liver transplants that extends organ preservation time. The company's projected revenue growth of 30% this year underscores the strong momentum in a global expansion opportunity. Veeva Systems (NYSE: VEEV) offers cloud-based software that streamlines clinical, regulatory, and commercial processes for life sciences companies. Serving over 1,000 customers, including major pharmaceutical companies and emerging biotechs, Veeva's platform is well positioned to capitalize on the industry's increasing reliance on digital solutions for innovation and compliance. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics, Inspire Medical Systems, TransMedics Group, and Veeva Systems. The Motley Fool recommends Insulet, Krystal Biotech, and Novo Nordisk. The Motley Fool has a disclosure policy. 10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential was originally published by The Motley Fool
Yahoo
2 hours ago
- Yahoo
Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush
Wedbush analyst Laura Chico lowered the firm's price target on Edgewise Therapeutics (EWTX) to $35 from $40 and keeps an Outperform rating on the shares. Edgewise said the FDA has deemed CANYON data insufficient to support an accelerated filing for sevasemten in Becker muscular dystrophy, but the company will explore additional avenues to speed the process, and will seek full approval with GRAND CANYON, the analyst tells investors in a research note. Wedbush still sees several unanswered questions for sevasemten in DMD such as the patient population to be studied, the firm says. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on EWTX: Disclaimer & DisclosureReport an Issue Edgewise Therapeutics Announces Positive Sevasemten Results Morning Movers: Shell ticks higher after denying interest in BP deal Edgewise update in line with expectations, says Leerink Truist sees 'slight weakness' for Edgewise Therapeutics on regulatory feedback Promising Developments in Edgewise Therapeutics: A Buying Opportunity Amidst Regulatory Challenges Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
